Johnson & johnson's dual-targeting car t-cell therapy shows encouraging first results in large b-cell lymphoma

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting cd19/cd20 car t in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended phase 2 dose  milan , june 13, 2025 /prnewswire/ -- johnson & johnson (nyse: jnj) announced today the first clinical data from an ongoing phase 1b study for jnj-90014496 (jnj-4496), an investigational dual-targeting anti-cd19/cd20 bispecific autologous chimeric antigen receptor (car) t-cell therapy, being studied in patients with relapsed or refractory large b-cell lymphoma (r/r lbcl) who have not been previously treated with car t-cell therapy.1 findings demonstrate the potential of jnj-4496 in the treatment of patients with r/r lbcl, including r/r diffuse large b-cell lymphoma (dlbcl) – the most common type of aggressive lymphoma, a blood cancer that originates in the lymphatic system.1,2 these data were presented as an oral presentation at the 2025 european hematology association (eha) congress (abstract #s239).1 jnj-4496, formerly known as c-car039, is a dual-targeting car t designed to bind to both cd19 and cd20 antigens — two cell surface proteins commonly expressed on malignant b-cells. this design, including a 4-1bb costimulatory domain, is intended to enhance binding strength and persistence, also potentially addressing common mechanisms of resistance in relapsed or refractory disease.
CAR Ratings Summary
CAR Quant Ranking